Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
2
Alisertib Phase 2 Combo Trial Launches in Small Cell Lung Cancer
3
Dr Herzberg on the Expanding Toolkit in KRAS-Mutant Non–Small Cell Lung Cancer
4
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
5